Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy
Phase 2
- Conditions
- Liver CancerHepatoCellular Carcinoma
- Interventions
- Procedure: TACE (Transcatheter Arterial Chemoembolization)Biological: IKC (Immune Killer Cells)
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Ivy Life Sciences, Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT03592706
- Locations
- 🇨🇳
Tri Service General Hospital, Taipei, Taiwan
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
Phase 1
Completed
- Conditions
- NSCLC Stage IVHepatocellular Carcinoma by BCLC StageLung CancerLiver CancerNSCLC Stage IIIB
- Interventions
- Biological: Immune Killer Cells (IKC)
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Ivy Life Sciences, Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT03515252
A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV
- Interventions
- Biological: Immune Killer Cells (IKC)
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Ivy Life Sciences, Co., Ltd
- Target Recruit Count
- 26
- Registration Number
- NCT03499834
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Tri Service General Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath